Cited by 922Inflammatory Bowel DiseaseGut microbiota and healthMicroscopic Colitis

Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

Open access
Rossen, Noortje G., Fuentes, Susana, van der Spek, Mirjam J., Tijssen, Jan G., Hartman, Jorn H.A., Duflou, Ann, Löwenberg, Mark, van den Brink, Gijs R. +5 more·2015·Gastroenterology

Abstract

Background & aims Several case series have reported the effects of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). We assessed the efficacy and safety of FMT for patients with UC in a double-blind randomized trial.Methods Patients with mild to moderately active UC (n = 50) were assigned to groups that underwent FMT with feces from healthy donors or were given autologous fecal microbiota (control); each transplant was administered via nasoduodenal tube at the start of the study and 3 weeks later. The study was performed at the Academic Medical Center in Amsterdam from June 2011 through May 2014. The composite primary end point was clinical remission (simple clinical colitis activity index scores ≤2) combined with ≥1-point decrease in the Mayo endoscopic score at week 12. Secondary end points were safety and microbiota composition by phylogenetic microarray in fecal samples.Results Thirty-seven patients completed the primary end point assessment. In the intention-to-treat analysis, 7 of 23 patients who received fecal transplants from healthy donors (30.4%) and 5 of 25 controls (20.0%) achieved the primary end point (P = .51). In the per-protocol analysis, 7 of 17 patients who received fecal transplants from healthy donors (41.2%) and 5 of 20 controls (25.0%) achieved the primary end point (P = .29). Serious adverse events occurred in 4 patients (2 in the FMT group), but these were not considered to be related to the FMT. At 12 weeks, the microbiota of responders in the FMT group was similar to that of their healthy donors; remission was associated with proportions of Clostridium clusters IV and XIVa.Conclusions In this phase 2 trial, there was no statistically significant difference in clinical and endoscopic remission between patients with UC who received fecal transplants from healthy donors and those who received their own fecal microbiota, which may be due to limited numbers. However, the microbiota of responders had distinct features from that of nonresponders, warranting further study. ClinicalTrials.gov Number: NCT01650038.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2015.03.045

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In two randomized controlled trials of UC patients, FMT responders showed a higher similarity to their donors than nonresponders.

    “Finally, in two randomized controlled trials of UC patients, FMT responders showed a higher similarity to their donors than nonresponders. 61,62”
  • One randomised controlled trial in ulcerative colitis, giving two faecal transplants via the upper GI route, showed no difference in clinical or endoscopic remission between the faecal transplant group and the control group given autologous stool.

    “One trial, in which two faecal transplants were given via the upper GI route, showed no difference in clinical or endoscopic remission between the faecal transplant group and the control group (given autologous stool).76”

    From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [76]

  • Two randomised controlled trials of FMT in ulcerative colitis since that meta-analysis show discrepant results.

    “Since that meta-analysis, two randomised controlled trials in UC show discrepant results.”

    From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [76]

  • In Moayyedi et al., remission (full Mayo score <3 and complete mucosal healing) was achieved in 24% of FMT patients and 5% of placebo patients.

    “Remission (full Mayo score <3 and complete mucosal healing) was achieved in 24% of patients after FMT and 5% with placebo; stool from patients receiving FMT had greater microbial diversity than that of patients given placebo.”
  • In Moayyedi et al., 75 patients with active UC were randomized to weekly FMT or water enema for 6 weeks, and there was a statistically significant difference in remission, the primary outcome, between groups.

    “In the study by Moayyedi et. al, seventy-five patients with active UC were randomized to a weekly FMT or water enema for 6 weeks, and there was a statistically significant difference in remission, the primary outcome, between the two groups.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., Zoetendal, E. G., D’Haens, G. R., & Ponsioen, C. Y.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Wageningen University & Research (NL)
Corresponding author
Ponsioen, Cyriel Y.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2015-07
Volume
149
Issue
1
Pages
110-118.e4
ISSN
0016-5085 (ISSN-L)
OpenAlex
W1994882377
Cited by
921
References
29
Citations by year
2026: 30 · 2025: 45 · 2024: 64 · 2023: 69 · 2022: 86 · 2021: 93 · 2020: 128 · 2019: 113 · 2018: 84 · 2017: 87 · 2016: 83 · 2015: 36
FWCI
66.05
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Socio-Environmental Systems Modeling (acceptedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Epidemiology › Microscopic Colitis
Keywords
fecal microbiota transplantation, ulcerative colitis, clinical remission, endoscopic remission, Clostridium cluster XIVa, Clostridium cluster IV, gut microbiota composition, adverse events
MeSH terms
Adult, Aged, Biological Therapy, Colitis, Ulcerative, Double-Blind Method, Feces, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Remission Induction, Treatment Outcome, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review